NEWRON PHARMACEUTICALS SPA (NP5.DE) Stock Price & Overview
FRA:NP5 • IT0004147952
Current stock price
The current stock price of NP5.DE is 16.6 EUR. Today NP5.DE is down by -3.71%. In the past month the price decreased by -17.82%. In the past year, price increased by 144.12%.
NP5.DE Key Statistics
- Market Cap
- 344.616M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.66
- Dividend Yield
- N/A
NP5.DE Stock Performance
NP5.DE Stock Chart
NP5.DE Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to NP5.DE. When comparing the yearly performance of all stocks, NP5.DE is one of the better performing stocks in the market, outperforming 95.18% of all stocks.
NP5.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to NP5.DE. Both the profitability and the financial health of NP5.DE get a neutral evaluation. Nothing too spectacular is happening here.
NP5.DE Earnings
On March 24, 2026 NP5.DE reported an EPS of -0.66 and a revenue of 7.23M. The company beat EPS expectations (2.55% surprise) and beat revenue expectations (86.48% surprise).
NP5.DE Forecast & Estimates
9 analysts have analysed NP5.DE and the average price target is 53.22 EUR. This implies a price increase of 220.62% is expected in the next year compared to the current price of 16.6.
For the next year, analysts expect an EPS growth of -74.33% and a revenue growth -22.71% for NP5.DE
NP5.DE Groups
Sector & Classification
NP5.DE Financial Highlights
Over the last trailing twelve months NP5.DE reported a non-GAAP Earnings per Share(EPS) of -0.66. The EPS decreased by -177.65% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 42.3% | ||
| ROA | 41.25% | ||
| ROE | 1600.95% | ||
| Debt/Equity | 11.8 |
NP5.DE Ownership
NP5.DE Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| 1SAN | SANOFI | 9.77 | 100.393B | ||
| SAN | SANOFI | 9.74 | 100.102B | ||
| SNW | SANOFI | 9.73 | 100.041B | ||
| UCB | UCB SA | 25.72 | 51.448B | ||
| UNC | UCB SA | 25.39 | 50.806B | ||
| 1MRK | MERCK KGAA | 13.21 | 48.348B | ||
| MRK | MERCK KGAA | 13.28 | 47.739B | ||
| 1BAYN | BAYER AG-REG | 8.59 | 39.493B | ||
| BAYN | BAYER AG-REG | 8.48 | 38.997B | ||
| IPN | IPSEN | 13.73 | 14.038B | ||
| REC | RECORDATI INDUSTRIA CHIMICA | 17.45 | 10.457B | ||
| TUB | FINANCIERE DE TUBIZE | N/A | 9.77B | ||
| VIRP | VIRBAC SA | 16.3 | 2.945B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Frankfurt Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the European exchanges | Find stocks with similar Fundamental rating on the European exchanges | Find the competitors with the best technical ratings on the European exchanges | Find the competitors with the best fundamentals on the European exchanges | Find the competitors with the best valuation on the European exchanges | Find the competitors with the best dividend on the European exchanges | Find the competitors with the best analyst ratings on the European exchanges
About NP5.DE
Company Profile
Newron Pharmaceuticals SpA operates as a biopharmaceutical company. The company is headquartered in Bresso, Milano and currently employs 22 full-time employees. The company went IPO on 2006-12-12. The company focuses on the discovery and development of pharmaceutical products. The firm is engaged in discovering and developing new therapies for diseases of the Central Nervous System (CNS) and pain. The firm undertakes phase III trials with safinamide molecule for the treatment of patients with Parkinson’s disease. Newron Pharmaceuticals SpA develops ralfinamide, a molecule for the treatment of neuropathic pain. Its additional projects, such as HF0220 for neuroprotection, NW-3509 for the treatment of schizophrenia, as well as pruvanserin and sarizotan for treatment of CNS diseases, are at various stages of preclinical and clinical development.
Company Info
IPO: 2006-12-12
NEWRON PHARMACEUTICALS SPA
via Antonio Meucci 3
Bresso MILANO IT
Employees: 22
Phone: 39026103461
NEWRON PHARMACEUTICALS SPA / NP5.DE FAQ
Can you describe the business of NEWRON PHARMACEUTICALS SPA?
Newron Pharmaceuticals SpA operates as a biopharmaceutical company. The company is headquartered in Bresso, Milano and currently employs 22 full-time employees. The company went IPO on 2006-12-12. The company focuses on the discovery and development of pharmaceutical products. The firm is engaged in discovering and developing new therapies for diseases of the Central Nervous System (CNS) and pain. The firm undertakes phase III trials with safinamide molecule for the treatment of patients with Parkinson’s disease. Newron Pharmaceuticals SpA develops ralfinamide, a molecule for the treatment of neuropathic pain. Its additional projects, such as HF0220 for neuroprotection, NW-3509 for the treatment of schizophrenia, as well as pruvanserin and sarizotan for treatment of CNS diseases, are at various stages of preclinical and clinical development.
What is the stock price of NEWRON PHARMACEUTICALS SPA today?
The current stock price of NP5.DE is 16.6 EUR. The price decreased by -3.71% in the last trading session.
What is the dividend status of NEWRON PHARMACEUTICALS SPA?
NP5.DE does not pay a dividend.
What is the ChartMill technical and fundamental rating of NP5 stock?
NP5.DE has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
Can you provide the sector and industry classification for NEWRON PHARMACEUTICALS SPA?
NEWRON PHARMACEUTICALS SPA (NP5.DE) operates in the Health Care sector and the Pharmaceuticals industry.
What is the market capitalization of NP5 stock?
NEWRON PHARMACEUTICALS SPA (NP5.DE) has a market capitalization of 344.62M EUR. This makes NP5.DE a Small Cap stock.